Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BVI Launches PODEYE Hydrophobic Monofocal IOL in Japan | ||
By: GlobeNewswire - 18 Apr 2024 | Back to overview list |
|
Second BVI Market Debut in Less Than Twelve Months
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- BVI, the most dynamic, diversified company in ophthalmology, announced today the official launch of the PODEYE hydrophobic monofocal IOL in Japan following approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The achievement represents another significant step in BVI’s plan to launch its range of IOLs in Japan over the near-term. Being unveiled at the Japanese Ophthalmic Society (JOS) annual meeting in Tokyo, PODEYE is now available for commercial use and available to surgeons across the country. “Our commitment to the Japanese ophthalmic market is a clear priority for BVI. The PODEYE launch continues to execute on our strategic vision and global expansion. We are set to equip surgeons with more solutions to enhance patient care. Anticipate more groundbreaking product launches from us in Japan and many other major markets globally.” said Shervin Korangy, President and CEO of BVI. Stability Made Simple. Focus on Safety Moreover, the company has also demonstrated market-wide expertise in IOL material development. Alongside its patented GFY material featured exclusively in BVI lenses, BVI also develops and supplies approximately 20% of IOL material for competing IOL companies globally from its facility in Florida, US. About BVI For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Head of BVI Corporate Communications: adawson@bvimedical.com 1 Market Scope Data |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |